Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects
Completed · Phase 4 · Has a placebo group
Conditions studied: Prolonged QTc Interval
In brief
Randomized, single-dose, double-blind, placebo and active controlled, four-period crossover study to evaluate the effect of deferiprone on QTc prolongation after administration of a single therapeutic (33 mg/kg) and supratherapeutic(50 mg/kg) oral doses of deferiprone in healthy volunteers as compared to placebo treatment.
Key facts
- Study ID
- NCT01860703
- Run by
- ApoPharma
- People needed
- 50
- Starts
- 2012-11-01
- Expected to finish
- 2013-07-01
- Last updated by the study team
- 2014-11-12
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
Where it is running
- Celerion — Tempe, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.